Niacin for primary and secondary prevention of cardiovascular events

To assess benefits and harms of combination therapy including niacin and other lipid-modifying drugs versus other lipid-modifying drugs alone or niacin versus placebo or usual care in patients with or at risk of CVD disease, in terms of mortality and CVD events.

This is a protocol.

Share/Save